Cyclosporine protects the heart during aortic valve surgery

Archive ouverte

Chiari, P. | Angoulvant, D. | Mewton, N. | Desebbe, O. | Obadia, J. F. | Robin, J. | Farhat, F. | Jegaden, O. | Bastien, O. | Lehot, J. J. | Ovize, Michel

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. BACKGROUND: Part of the myocardial damage occurring during cardiac surgery is a consequence of reperfusion injury. Cyclosporine, a potent inhibitor of the opening of the mitochondrial permeability transition pore, attenuates reperfusion injury in patients with acute ST-segment elevation myocardial infarction. This study investigated whether the administration of cyclosporine just before the aortic cross-unclamping would reduce myocardial injury in patients undergoing aortic valve surgery. METHODS: This study was a monocentric, prospective, randomized, single-blinded, controlled trial. Sixty-one patients, scheduled for elective aortic valve surgery, were randomly assigned (computer-generated randomization sequence) to receive either an intravenous bolus of cyclosporine (2.5 mg/kg, cyclosporine group, n = 30) or normal saline (control group, n = 31) 10 min before aortic cross-unclamping. The primary endpoint was the 72-h area under the curve for cardiac troponin I. RESULTS: Both groups were similar with respect to baseline characteristics and aortic cross-clamping duration. A significant 35% reduction of area under the curve for cardiac troponin I was observed in the cyclosporine group compared with the control group (242 +/- 225 vs. 155 +/- 71 arbitrary units, mean +/- SD; mean difference, -86.2 +/- 42.5; 95% CI, -172.3 to -0.1; P = 0.03). Cyclosporine beneficial effect remained significant after adjustment for aortic cross-clamping duration in each group (mean difference, -88 +/- 34, 95% CI, -157 to -19; P = 0.01). None of the treated patients had significant side effects (odds ratio, 0.64; 95% CI, 0.16 to 2.55; P = 0.52). CONCLUSIONS: Cyclosporine administration at the time of reperfusion protects against reperfusion injury in patients undergoing aortic valve surgery. The clinical benefit of this protection requires confirmation in a larger clinical trial.

Consulter en ligne

Suggestions

Du même auteur

Tissue hemoglobin monitoring is unable to follow variations of arterial hemoglobin during transitions from pulsatile to constant flow in cardiac surgery

Archive ouverte | Desebbe, O. | CCSD

International audience

Therapeutic management changes and mortality rates over 30 years in ventricular septal rupture complicating acute myocardial infarction

Archive ouverte | Morillon-Lutun, S. | CCSD

International audience

Is a severe preoperative condition a contraindication for aortic valve-sparing reimplantation in type A aortic dissection?

Archive ouverte | Lapeze, J. | CCSD

BACKGROUND: Type A aortic dissection (TAAD) surgical management is still under debate. The purpose of this study was to demonstrate the feasibility and safety of the aortic valve-sparing root reconstruction (AVSR) procedure in 92 ...

Chargement des enrichissements...